Cargando…

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding enzyme activated by DNA breaks and involved in DNA repair and other cellular processes. Poly(ADP-ribose) polymerase activity can be higher in cancer than in adjacent normal tissue, but cancer predisposition is reported to be greater...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaremba, T, Ketzer, P, Cole, M, Coulthard, S, Plummer, E R, Curtin, N J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720202/
https://www.ncbi.nlm.nih.gov/pubmed/19568233
http://dx.doi.org/10.1038/sj.bjc.6605166
_version_ 1782170115231449088
author Zaremba, T
Ketzer, P
Cole, M
Coulthard, S
Plummer, E R
Curtin, N J
author_facet Zaremba, T
Ketzer, P
Cole, M
Coulthard, S
Plummer, E R
Curtin, N J
author_sort Zaremba, T
collection PubMed
description BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding enzyme activated by DNA breaks and involved in DNA repair and other cellular processes. Poly(ADP-ribose) polymerase activity can be higher in cancer than in adjacent normal tissue, but cancer predisposition is reported to be greater in individuals with a single-nucleotide polymorphism (SNP) V762A (T2444C) in the catalytic domain that reduces PARP-1 activity. METHODS: To resolve these divergent observations, we determined PARP-1 polymorphisms, PARP-1 protein expression and activity in a panel of 19 solid and haematological, adult and paediatric human cancer cell lines. RESULTS: There was a wide variation in PARP activity in the cell line panel (coefficient of variation, CV=103%), with the lowest and the highest activity being 2460 pmol PAR/10(6) (HS-5 cells) and 85 750 pmol PAR/10(6) (NGP cells). Lower variation (CV=32%) was observed in PARP-1 protein expression with the lowest expression being 2.0 ng μg(−1) (HS-5 cells) and the highest being 7.1 ng μg(−1) (ML-1 cells). The mean activity in the cancer cells was 45-fold higher than the mean activity in normal human lymphocytes and the PARP-1 protein levels were 23-fold higher. CONCLUSIONS: Surprisingly, there was no significant correlation between PARP activity and PARP-1 protein level or the investigated polymorphisms, T2444C and CA.
format Text
id pubmed-2720202
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27202022010-07-21 Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines Zaremba, T Ketzer, P Cole, M Coulthard, S Plummer, E R Curtin, N J Br J Cancer Translational Therapeutics BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding enzyme activated by DNA breaks and involved in DNA repair and other cellular processes. Poly(ADP-ribose) polymerase activity can be higher in cancer than in adjacent normal tissue, but cancer predisposition is reported to be greater in individuals with a single-nucleotide polymorphism (SNP) V762A (T2444C) in the catalytic domain that reduces PARP-1 activity. METHODS: To resolve these divergent observations, we determined PARP-1 polymorphisms, PARP-1 protein expression and activity in a panel of 19 solid and haematological, adult and paediatric human cancer cell lines. RESULTS: There was a wide variation in PARP activity in the cell line panel (coefficient of variation, CV=103%), with the lowest and the highest activity being 2460 pmol PAR/10(6) (HS-5 cells) and 85 750 pmol PAR/10(6) (NGP cells). Lower variation (CV=32%) was observed in PARP-1 protein expression with the lowest expression being 2.0 ng μg(−1) (HS-5 cells) and the highest being 7.1 ng μg(−1) (ML-1 cells). The mean activity in the cancer cells was 45-fold higher than the mean activity in normal human lymphocytes and the PARP-1 protein levels were 23-fold higher. CONCLUSIONS: Surprisingly, there was no significant correlation between PARP activity and PARP-1 protein level or the investigated polymorphisms, T2444C and CA. Nature Publishing Group 2009-07-21 2009-06-30 /pmc/articles/PMC2720202/ /pubmed/19568233 http://dx.doi.org/10.1038/sj.bjc.6605166 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Zaremba, T
Ketzer, P
Cole, M
Coulthard, S
Plummer, E R
Curtin, N J
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
title Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
title_full Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
title_fullStr Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
title_full_unstemmed Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
title_short Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
title_sort poly(adp-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720202/
https://www.ncbi.nlm.nih.gov/pubmed/19568233
http://dx.doi.org/10.1038/sj.bjc.6605166
work_keys_str_mv AT zarembat polyadpribosepolymerase1polymorphismsexpressionandactivityinselectedhumantumourcelllines
AT ketzerp polyadpribosepolymerase1polymorphismsexpressionandactivityinselectedhumantumourcelllines
AT colem polyadpribosepolymerase1polymorphismsexpressionandactivityinselectedhumantumourcelllines
AT coulthards polyadpribosepolymerase1polymorphismsexpressionandactivityinselectedhumantumourcelllines
AT plummerer polyadpribosepolymerase1polymorphismsexpressionandactivityinselectedhumantumourcelllines
AT curtinnj polyadpribosepolymerase1polymorphismsexpressionandactivityinselectedhumantumourcelllines